Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 3/20 | 0.38 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.38 |
| ▸ | MET | P08581 | 3/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.37 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24958866 | 0.93 | BRD4 (0.40) | LGALS3LGALS1METIRAK4DPP4 | |
| SCHEMBL24958864 | 0.93 | BRD4 (0.40) | LGALS3LGALS1METIRAK4DPP4 | |
| SCHEMBL24958717 | 0.93 | CHRNB2 (0.39) | LGALS3LGALS1METDPP4CHRNB2 | |
| SCHEMBL24958695 | 0.89 | DPP4 (0.37) | LGALS3LGALS1METIRAK4DPP4 | |
| SCHEMBL24958698 | 0.85 | CHRNB2 (0.38) | LGALS3LGALS1METIRAK4DPP4 | |
| SCHEMBL29848152 | 0.81 | LGALS3 (0.51) | LGALS3LGALS1 | |
| SCHEMBL24956536 | 0.80 | MET (0.49) | METIRAK4 | |
| SCHEMBL24958696 | 0.76 | SOST (0.43) | LGALS3LGALS1METIRAK4DPP4 | |
| SCHEMBL17806601 | 0.75 | GSK3B (0.41) | DPP4 | |
| SCHEMBL25406857 | 0.71 | AKR1A1 (0.36) | LGALS3LGALS1IRAK4KCNJ5CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | LGALS3 548/4885LGALS1 497/4885MET 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.